The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin)

Απλή σελίδα τεκμηρίου
dc.contributor.authorKaba, S. E.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorConrad, C.en
dc.contributor.authorGleason, M. J.en
dc.contributor.authorNewman, R.en
dc.contributor.authorLevin, V. A.en
dc.contributor.authorYung, W. K.en
dc.date.accessioned2015-11-24T19:23:08Z
dc.date.available2015-11-24T19:23:08Z
dc.identifier.issn0167-594X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22253
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents/adverse effects/blood/*therapeutic useen
dc.subjectBrain Neoplasms/*drug therapy/pathologyen
dc.subjectChilden
dc.subjectChild, Preschoolen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectDose-Response Relationship, Drugen
dc.subjectFemaleen
dc.subjectGlioma/*drug therapy/pathologyen
dc.subjectHeadache/chemically induceden
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Recurrence, Local/*drug therapyen
dc.subjectSkin/drug effects/pathologyen
dc.subjectTime Factorsen
dc.subjectTretinoin/adverse effects/blood/*therapeutic useen
dc.titleThe treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin)en
heal.abstractMalignant gliomas continue to be a significant source of mortality in young and middle aged adults. The introduction of new treatment strategies and multidisciplinary approaches has improved the outcome of patients with these tumors only slightly. Because retinoic acid has growth inhibitory activity against glioma and neuroblastoma cells in cultures, we assessed the efficacy of all-trans-retinoic acid in the treatment of recurrent cerebral gliomas. Thirty-six patients with recurrent cerebral gliomas were entered in the study and treated with 120 or 150 mg/ m2/day of all-trans-retinoic acid as a single agent. The drug was given for 3 weeks followed with one week of rest. Two blocks of 4 weeks constituted one course of treatment. One (3%) of 34 evaluable patients had a minor response and 14 (41%) had stable disease. In the rest of the patients (56%), tumors continued to progress despite treatment. The median time to progression of all evaluable patients was 8 weeks, and for the responders was 17 weeks. The higher dose level (150 mg/m2) was associated with high incidence of headache, which responded to dose reduction. The lower dose level was very well tolerated, with mild, mainly dermatological toxicity. All-trans-retinoic acid as a single agent has no significant activity against recurrent cerebral gliomas.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9210061-
heal.journalNameJ Neurooncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1997-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ